Scilex Holding Company, a Nasdaq-listed company, announced that d a binding Term Sheet had been signed between NeuroBiogen, a Korean company specializing in innovative new drugs, and Scilex Bio, a controlling interest of joint venture by Scilex Holding Company on December 10th, local time.

Under the terms of the agreement, Scilex Bio will be granted an exclusive worldwide license to develop and commercialize tisolagiline (KDS2010), an oral treatment for Alzheimer's disease and obesity that is in clinical development by NeuroBiogen.

The collaboration will leverage NeuroBiogen’s R&D capabilities for KDS2010 and Scilex’s commercialization expertise in the central nervous system and f